Stage IV NSCLC adenocarcinoma ALK+ with multiple brain mets, Considering AP26113 trial instead of WBRT.
From the ESMO 2013 released data, AP26113 is promising for brain mets. 8 of 10 patients with active brain mets got regression. The published data says most patients are on 180mg per day, but the trial is still a dose-finding study. As I don't tolerate well with targeted drug I have tried (Tarceva, Xalkori), just want to know if a lower dose AP26113 can get good response rate on brain mets, at least for maintenance.
Any input would be appreciated.